Taiho Pharmaceutical said on January 13 that it and UK-based Astex Pharmaceuticals, both Otsuka Pharmaceutical’s subsidiaries, entered into an exclusive license agreement with US Merck for their small-molecule drug discovery program targeting SHP2. Back in January 2020, the three parties…
To read the full story
Related Article
- Taiho, Astex in KRAS Licensing Deal with US Merck
January 7, 2020
BUSINESS
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





